Search results
Placebo response in RCT for antidepressant may not always be the ‘villain’ to fight: are KOR...
Nature· 6 days agoEmilio Merlo Pich was the Global Head of R&D in Alfasigma SPA (I) from 2019 to 2022. In 2023, as CEO of Gelf Heath srl, he was consultant for Relmada Therapeutics Inc. (USA), Centessa Pharmaceuticals (USA), Novavido (I), and G-Factor (I).
Diabetes drug benefits heart failure patients in a surprising way
Futurity· 22 hours agoA new study has revealed surprising new insights into how SGLT2 inhibitor drugs, originally...
Novo’s Ozempic slashes risk of death in kidney disease study
Detroit News· 5 days agoPatients with kidney disease caused by diabetes were one-fifth less likely to die of any cause...
GLP-2 Analog Reduces Need for Parenteral Support in Patients With Rare GI Condition
MedPage Today· 6 days agoBetter outcomes in short bowel syndrome and intestinal failure with apraglutide vs placebo
Not All COVID Patients Benefit From JAK Inhibitor
MedPage Today· 1 day agoDeath within 28 days of starting treatment occurred in 5.6% of patients with body mass index (BMI) values >30, compared with 9.2% of those assigned to ...
No, sugar doesn’t make your kids hyperactive
Salon.com· 22 hours agoThe belief that eating sugary foods and drinks leads to hyperactivity has steadfastly persisted for decades. As a neuroscientist who has studied the...
Novartis’ atrasentan shows to reduce proteinuria in Phase III IgAN trial
Clinical Trials Arena via Yahoo Finance· 2 days agoNovartis has unveiled interim results from the Phase III ALIGN clinical trial where atrasentan...
Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday?
Benzinga via Yahoo Finance· 24 hours agoInsmed Incorporated (NASDAQ:INSM) shares are trading higher after the company released topline...
Plozasiran Paves RNA Interference Path to Triglyceride Reduction
MedPage Today· 1 day agoIn such individuals, known to be at increased risk of atherosclerotic cardiovascular disease...
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major...
Digital Journal· 1 day agoThe mean reduction was 13.90 in the placebo group, 15.61 in the 10 mg group and 16.94 in the 20 mg group. A clear dose response and a clinically meaningful, but not statistically ...